A National, Open-label, Multicenter, Randomized, Comparative Phase IIb Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone (Rd)

Trial Profile

A National, Open-label, Multicenter, Randomized, Comparative Phase IIb Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone (Rd)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology AssociationResults validating the use of Serum-Free Light-Chains (sFLC) assay in patients being treated in GEM/PETHEMA clinical trials (GEM05menos65, GEM05MAS65, GEM2010MAS65 and GEM2012menos65), presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results assessing the role of Complete Response and Minimal Residual Disease in elderly newly diagnosed myeloma patients treated with Bortezomib plus melphalan and prednisone (VMP) and lenalidomide plus low-dose dexamethasone (Rd), presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results evaluating the factors associated with early death treated in two prospective trials (GEM05MAS65 and GEM2010MAS65), presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top